National study recommends starting SARS-CoV-2 : comparemela.

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network and Fred Hutchinson Cancer Center. The research, involving 22 cancer centers and research institutions in the United States and focusing on mRNA-based vaccines, published in The Lancet journal eClinicalMedicine.

Related Keywords

United States , Washington , University Of Washington , Seattle , American , Fred Hutch , Claire Hudson , E Donnall Thoma , Miguel Angel Perales , Joshua Hill , American Society For Transplantation , Fred Hutchinson Cancer Center , Novartis , Method Of Research , International Blood , Marrow Transplant Research , National Institutes Of Health , Myeloma Research Foundation , Weil Cornell Medical College , University Of Washington School Medicine , Lymphoma Society , National Marrow Donor Program Be The , Memorial Sloan Kettering Cancer Center , Blood Marrow Transplant Clinical Trials Network , Pfizer , Fred Hutch Bone Marrow Transplant Program , National Cancer , Marrow Transplant Clinical Trials Network , Fred Hutchinson Cancer , Washington School , Nobel Prize , National Marrow Donor , Multiple Myeloma Research Foundation , American Society , Cellular Therapy , Adaptive Biotechnologies , National Institutes , Hutchinson Cancer Center , National Cancer Institute Designated ,